Welcome to our dedicated page for AMARIN PLC\UK SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AMARIN PLC\UK's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AMARIN PLC\UK's regulatory disclosures and financial reporting.
Amarin Corporation reported Q1 2026 total net revenue of $45.1 million, up 7% from Q1 2025, driven by stable U.S. VASCEPA sales, higher rest-of-world product revenue, and an 84% increase in licensing and royalty revenue.
Total operating expenses fell 31% to $29.1 million, mainly from the June 2025 Global Restructuring and lower selling, general and administrative costs, which declined 42%. Operating loss narrowed to $11.3 million, and net loss improved to $10.5 million, or $(0.03) per ordinary share.
The company generated positive cash flow, with cash and investments rising to $307.8 million as of March 31, 2026, and remained debt free. On a non-GAAP basis, net loss was reduced to $1.8 million, reflecting add-backs for stock-based compensation, restructuring and a litigation settlement.
Amarin director Patrice Eadon Bonfiglio reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, 2026, previously granted restricted stock units vested, resulting in the acquisition of 838 ADSs through a derivative exercise. In connection with this vesting, the company withheld 403 ADSs at a value of $14.98 per ADS to cover tax obligations, which the filing notes is not a market sale under Rule 16b-3. After these transactions, Bonfiglio directly owns 836 ADSs. Footnotes explain that one ADS represents twenty ordinary shares following an ADS ratio change and that the RSUs were granted under Amarin’s 2020 Stock Incentive Plan, vesting in three equal annual installments.
Amarin Corporation director Paul Cohen reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, 838 ADS were acquired at $0.00 per share through the exercise of Restricted Stock Units, reflecting an equity award vesting. On the same date, 403 ADS at $14.98 per share were withheld by Amarin to cover tax liabilities tied to this vesting, which a footnote clarifies is not a market sale of securities under Rule 16b‑3. Following these transactions, Cohen directly held 836 ADS. Footnotes note a prior ADS ratio change, with each ADS now representing twenty ordinary shares and each RSU representing a contingent right to receive twenty ordinary shares or cash.
Amarin director Louis Sterling III exercised 838 Restricted Stock Units on April 18, 2026, receiving 838 American Depositary Shares. The issuer withheld 403 ADS to cover tax liability at $14.98 per share. Following these transactions, he holds 4,049 ADS directly.
Amarin director Odysseas D. Kostas reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, he exercised 838 Restricted Stock Units (RSUs), acquiring 838 ADS at a stated price of $0.00 per ADS.
In connection with this vesting, 403 ADS were withheld by Amarin to cover related tax liabilities, as described in the filing as a tax-withholding disposition under Rule 16b-3, not a market sale. After these transactions, Kostas directly held 836 ADS.
The RSUs stem from a grant of 2,514 RSUs made on April 18, 2024 under Amarin’s 2020 Stock Incentive Plan, vesting in three equal installments on April 18, 2025, 2026, and 2027. Each RSU represents a contingent right to receive twenty ordinary shares or cash, and all reported amounts reflect a prior ADS ratio change.
Diane E. Sullivan, a director of Amarin Corporation plc, exercised previously granted restricted stock units on April 18, 2026 to acquire 838 American Depositary Shares. In connection with vesting, 403 ADSs were withheld to satisfy tax obligations, not sold in the market. Following these transactions, she holds 836 ADSs directly.
Amarin director Keith Horn exercised 838 Restricted Stock Units, converting them into 838 American Depositary Shares (ADS) on April 18, 2026 at a conversion price of $0 per share. In a related tax-withholding disposition, 403 ADS were delivered at $14.98 per share to cover taxes. Following these equity award transactions, he directly holds 836 ADS.
Amarin Corporation director Oliver O’Connor reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, he acquired 838 ADSs through the vesting and conversion of Restricted Stock Units, while 438 ADSs were withheld by the company to cover tax obligations.
After these transactions, he directly held 801 ADSs. A prior grant on April 18, 2024 covered 2,514 RSUs vesting in three equal installments on April 18, 2025, 2026 and 2027. Each RSU represents a contingent right to receive one ADS, and each ADS currently represents twenty ordinary shares after an ADS ratio change.
Amarin Corporation is asking shareholders at its May 13, 2026 AGM to re-elect seven directors, approve 2025 executive pay on an advisory basis, and reappoint Ernst & Young as auditor. The company highlights a 2025 restructuring, ending the year with $303 million in cash, no debt, and positive Q4 2025 cash flow, with expected annual savings of $70 million.
Shareholders are asked to renew authority for the Board to issue new ordinary shares up to a nominal £37,750,000 (about 18% of existing share capital) and to approve an amended 2020 Stock Incentive Plan adding 15,000,000 ordinary shares to the reserve. A special resolution would also allow issuances for cash without UK pre-emption rights up to a nominal £20,970,000 (about 10% of existing share capital), and another would permit electronic AGM notices via a website to cut printing and mailing costs.